Dear Dr. Knipfer:


We acknowledge receipt of your submissions dated February 24, April 16, May 4, and June 10, 2004. These supplemental new drug applications propose the following changes: in the labeling sections SPECIAL POPULATIONS - PEDIATRICS, PEDIATRIC USE, DOSAGE AND ADMINISTRATION and DESCRIPTION section of the package insert for the treatment of symptomatic GERD, nonerosive esophagitis and erosive esophagitis in patients 12-17 years of age.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert,) and/or submitted labeling (package insert submitted June 10, 2004).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-406/S-057, NDA 21-281/S-014, and NDA 21-428/S-004." Approval of these submissions by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have completed studies for ages 1-11 (NDA 20-406/S-047) and ages 12-17 (with this submission), and plan to initiate studies in children less than 1 year of age after the completion of your required rat toxicity study.

In addition, submit three copies of the introductory promotional materials that you propose to use for these products. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Melissa Hancock Furness, Regulatory Health Project Manager, at (301) 827-7450.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D., M.S.
Director
Division of Gastrointestinal & Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Joyce Korvick
6/17/04 01:54:36 PM
for Dr. Robert Justice